SCNI Share Price Performance
US$0.75
-2.69 (-78.20%)
Price US$0.75
Share Pricen/a
This Is Why Scinai Immunotherapeutics Ltd.'s (NASDAQ:SCNI) CEO Compensation Looks Appropriate
Dec 15
Scinai Immunotherapeutics Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
SCNI Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Scinai Immunotherapeutics Ltd. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- 0.11
- -146.99%
- 30.25%
- 3.7%
About SCNI
- Founded
- 2003
- Employees
- 31
- CEO
- WebsiteView website
Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson’s syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
